PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+19.36%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$95.4M
AUM Growth
+$5.28M
(+5.9%)
Cap. Flow
-$3.93M
Cap. Flow
% of AUM
-4.12%
Top 10 Holdings %
Top 10 Hldgs %
38.61%
Holding
118
New
12
Increased
17
Reduced
46
Closed
16
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$1.17M |
| 2 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$1.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.02M |
| 4 |
ATHX
Athersys, Inc. Common Stock
ATHX
|
+$556K |
| 5 |
Veracyte
VCYT
|
+$506K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CryoPort
CYRX
|
+$1.36M |
| 2 |
JetBlue
JBLU
|
+$1.05M |
| 3 |
AtriCure
ATRC
|
+$959K |
| 4 |
NCR Voyix
VYX
|
+$854K |
| 5 |
SNAK
Inventure Foods, Inc.
SNAK
|
+$705K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.26% |
| 2 | Technology | 10.27% |
| 3 | Industrials | 8.69% |
| 4 | Communication Services | 3.79% |
| 5 | Financials | 2.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Axogen
AXGN
$2.06B
| $10.4M | 10.94% |
539,598
-15,194
| -3% | -$255K |
2013 Q3
16 quarters
|
|
2
Abbott
ABT
$178B
| $4.43M | 4.64% |
83,060
+350
| +0.4% | +$17.6K |
2014 Q1
14 quarters
|
|
3
Rockwell Medical
RMTI
$30.9M
| $3.75M | 3.93% |
3,982
-19
| -0.5% | -$14.5K |
2013 Q2
17 quarters
|
|
4
NeoGenomics
NEO
$2.17B
| $3.43M | 3.59% |
308,300
-500
| -0.2% | -$4.87K |
2013 Q2
17 quarters
|
|
|
5
Vericel Corp
VCEL
$2.06B
| $3.38M | 3.54% |
562,600
+305,000
| +118% | +$1.17M |
2014 Q3
12 quarters
|
|
6
LeMaitre Vascular
LMAT
$1.89B
| $2.88M | 3.02% |
77,075
-8,175
| -10% | -$278K |
2017 Q1
2 quarters
|
|
|
VYNT
7
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $2.18M | 2.28% |
5,378
-144
| -3% | -$75.1K |
2015 Q4
7 quarters
|
|
8
Idexx Laboratories
IDXX
$41.7B
| $2.18M | 2.28% |
14,000
| – | – |
2013 Q3
16 quarters
|
|
9
Apyx Medical
APYX
$108M
| $2.11M | 2.21% |
623,685
+23,868
| +4% | +$61.6K |
2015 Q1
10 quarters
|
|
|
10
AtriCure
ATRC
$2.91B
| $2.08M | 2.18% |
92,950
-42,418
| -31% | -$959K |
2013 Q2
17 quarters
|
|
|
11
CryoPort
CYRX
$843M
| $2M | 2.09% |
202,990
-184,491
| -48% | -$1.36M |
2016 Q1
6 quarters
|
|
|
CSII
12
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.87M | 1.96% |
66,550
-2,000
| -3% | -$60.8K |
2013 Q2
17 quarters
|
|
13
Pfizer
PFE
$166B
| $1.85M | 1.94% |
54,738
-264
| -0.5% | -$8.48K |
2013 Q2
17 quarters
|
|
14
AbbVie
ABBV
$501B
| $1.74M | 1.82% |
19,550
-100
| -0.5% | -$7.61K |
2014 Q3
12 quarters
|
|
15
Integer Holdings
ITGR
$4.3B
| $1.72M | 1.8% |
33,550
-3,650
| -10% | -$167K |
2016 Q4
3 quarters
|
|
16
Microsoft
MSFT
$3.96T
| $1.58M | 1.65% |
21,185
-400
| -2% | -$29.2K |
2014 Q1
14 quarters
|
|
17
Eli Lilly
LLY
$1.08T
| $1.56M | 1.63% |
18,200
-250
| -1% | -$20.5K |
2013 Q2
17 quarters
|
|
18
DELISTED
Cogentix Medical, Inc.
CGNT
| $1.44M | 1.5% |
560,881
-84,422
| -13% | -$185K |
2015 Q2
9 quarters
|
|
19
Digital Turbine
APPS
$1.16B
| $1.38M | 1.44% |
911,080
+47,500
| +6% | +$56.2K |
2015 Q1
10 quarters
|
|
20
IZEA Worldwide
IZEA
$39.9M
| $1.3M | 1.37% |
45,928
-156
| -0.3% | -$1.35K |
2016 Q1
6 quarters
|
|
21
Aflac
AFL
$59.3B
| $1.26M | 1.32% |
30,900
+300
| +1% | +$12.1K |
2015 Q2
9 quarters
|
|
|
ZIXI
22
DELISTED
Zix Corporation
ZIXI
| $1.24M | 1.3% |
253,579
-10,800
| -4% | -$56.9K |
2013 Q2
17 quarters
|
|
|
ATRS
23
DELISTED
Antares Pharma, Inc.
ATRS
| $1.19M | 1.24% |
366,000
+356,000
| +3,560% | +$1.1M |
2016 Q3
4 quarters
|
|
24
AT&T
T
$158B
| $1.18M | 1.24% |
39,934
-2,847
| -7% | -$80.8K |
2015 Q3
8 quarters
|
|
25
CVS Health
CVS
$116B
| $1.16M | 1.21% |
14,200
+150
| +1% | +$11.9K |
2013 Q2
17 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Perkins Capital Management held 118 positions worth $95.4M, up 5.9% from $90.2M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Perkins Capital Management withdrew a net $3.93M in Q3 2017, closing 16 positions and reducing 46 holdings. Its most notable exit was JetBlue, an estimated $1.05M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 63% a quarter earlier, followed by Technology and Industrials.
Against the trend, Perkins Capital Management opened a new position in Bristol-Myers Squibb worth $1.12M.
- Perkins Capital Management's largest Q3 2017 buy was Bristol-Myers Squibb: 17,525 shares worth $1.12M.
- Perkins Capital Management added most to Vericel Corp in Q3 2017, an estimated $1.17M increase.
- Perkins Capital Management's biggest Q3 2017 reduction was CryoPort, cutting an estimated $1.36M.
- Perkins Capital Management fully exited JetBlue in Q3 2017, selling an estimated $1.05M.
- Perkins Capital Management's ten largest holdings make up 39% of its $95.4M portfolio in Q3 2017.
- Perkins Capital Management opened 12 new positions and closed 16 in Q3 2017.
- Perkins Capital Management's portfolio value rose 5.9% quarter-over-quarter to $95.4M.
Based on Perkins Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.